Evidence map›Paper›PMID 41809407›Full record

ReviewResearch (Washington, D.C.)2026

The Heterogeneity and Function of Stromal Cells in the Tumor Microenvironment.

Xuehai Wang, Songlin Li, Yang Xue, Xiao Liang, Xuelei Ma, Kun Zhang, Ying Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Research (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xuehai WangDepartment of Thoracic Surgery, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan Province, China.
Songlin LiDepartment of Oncology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan Province, China.
Yang XueDepartment of Thoracic Surgery, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan Province, China.
Xiao LiangDepartment of Biotherapy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Xuelei MaDepartment of Biotherapy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.ORCID https://orcid.org/0000-0002-9148-5001
Kun ZhangDepartment of Thoracic Surgery, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan Province, China.
Ying WangDepartment of Oncology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tumor microenvironment is a central determinant of cancer progression, metastatic spread, and therapeutic resistance. Once considered passive scaffolds, stromal cells are now recognized as heterogeneous, active regulators of tumor behavior. Recent single-cell and spatial multiomics studies have resolved functionally distinct stromal subtypes, each defined by characteristic molecular programs and spatial niches, with specialized roles in extracellular matrix remodeling, immune evasion, and angiogenesis. This review synthesizes evidence for bidirectional stromal-tumor cross-talk in which cytokine networks (e.g., transforming growth factor-beta, interleukin-6, and C-X-C motif chemokine ligand 12/C-X-C chemokine receptor 4) coordinate epithelial-mesenchymal transition, stemness, chemotaxis, and vascular remodeling. Building on these insights, this review also argues for subtype-specific biomarkers and multimodal therapeutic strategies to overcome stromal-mediated resistance. Integrating stromal heterogeneity into precision-oncology workflows through standardized, lineage-resolved profiling and real-time biomarker guidance will be essential for diagnostic refinement and personalized treatment.

Identifiers

PMID41809407
PMCPMC12968398

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.